Arteriosclerosis Obliterans Market Shows Promising Growth Prospects During the Forecast Period (2026-2036) Amid Evolving Treatment Landscape | DelveInsight

The arteriosclerosis obliterans market is anticipated to experience steady growth across the 7MM, supported by the increasing prevalence of diabetes and obesity, an aging population, enhanced PAD diagnosis, and growing demand for treatments aimed at reducing amputation risk and improving patients' quality of life. Additionally, the expected launch of emerging therapies such as Orforglipron (LY3502970; Eli Lily), Selexipag (NS-304; Nippon Shinyaku), CLBS12 (Lisata Therapeutics), VT-141 (Venturis Therapeutics), and others will further propel the market growth.

LAS VEGAS, Oct. 8, 2026 /PRNewswire/ -- Recently published Arteriosclerosis Obliterans Market Insights report includes a comprehensive understanding of current treatment practices, arteriosclerosis obliterans emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Arteriosclerosis Obliterans Market Summary

• The total arteriosclerosis obliterans treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest arteriosclerosis obliterans treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Arteriosclerosis obliterans is responsible for 95% of chronic occlusive arterial disease, most commonly affects patients over age 50, and affects men more than women 
• Leading arteriosclerosis obliterans companies, such as Eli Lily, Nippon Shinyaku, Lisata Therapeutics, Venturis Therapeutics, Regeneron Pharmaceuticals, BioGenCell, Vasa Therapeutics, and others, are developing new arteriosclerosis obliterans treatment drugs that can be available in the arteriosclerosis obliterans market in the coming years. 
• The promising arteriosclerosis obliterans therapies in clinical trials include Orforglipron (LY3502970), Selexipag (NS-304), CLBS12, VT-141, REGN7508/Cenvacibart, REGN9933/Amrecibart, BGC101, VS-214, and others.

Discover the future of the arteriosclerosis obliterans market @ https://www.delveinsight.com/report-store/arteriosclerosis-obliterans-market

Key Factors Driving the Growth of the Arteriosclerosis Obliterans Market 

• Rising Prevalence of Peripheral Artery Disease: The increasing incidence of peripheral artery disease (PAD), particularly among older adults, is driving demand for the diagnosis and treatment of arteriosclerosis obliterans. Growing rates of diabetes, hypertension, obesity, and cardiovascular disorders further contribute to disease prevalence.
• Advancements in Endovascular Treatments: Technological advances in angioplasty, drug-coated balloons, stents, atherectomy systems, and other minimally invasive interventions are improving treatment options for patients with arterial occlusive disease. These innovations can reduce procedural invasiveness and support wider adoption of endovascular therapies.
• Growing Adoption of Minimally Invasive Procedures: Increasing preference for minimally invasive vascular interventions is encouraging the use of catheter-based procedures over more invasive surgical approaches in appropriate patients. Shorter recovery times and reduced procedural burden are supporting the adoption of these technologies.
• Launch of Emerging Drugs: The dynamics of the arteriosclerosis obliterans market are expected to change in the coming years due to the launch of emerging therapies such as Orforglipron (LY3502970; Eli Lily), Selexipag (NS-304; Nippon Shinyaku), CLBS12 (Lisata Therapeutics), VT-141 (Venturis Therapeutics), REGN7508/Cenvacibart (Regeneron Pharmaceuticals), REGN9933/Amrecibart (Regeneron Pharmaceuticals), BGC101 (BioGenCell), VS-214 (Vasa Therapeutics), and others.

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that among emerging therapies, selexipag represents one of the most advanced pharmacological candidates specifically targeting arteriosclerosis obliterans-associated intermittent claudication. If successful, selexipag could provide a differentiated oral therapy by improving vascular tone and blood flow beyond currently available symptomatic treatments.

Arteriosclerosis Obliterans Market Analysis

• The treatment landscape for arteriosclerosis obliterans continues to center on symptom management, cardiovascular risk reduction, and revascularization, while disease-modifying pharmacological therapies remain limited. 
• Current pharmacological management primarily relies on cilostazol, supplemented by regionally used agents such as beraprost, limaprost, and sarpogrelate, particularly for treating intermittent claudication and related symptoms.
• The pipeline remains relatively limited and includes therapies such as orforglipron (LY3502970) from Eli Lilly, selexipag (NS-304) from Nippon Shinyaku, CLBS12 from Lisata Therapeutics, and VT-141 from Venturis Therapeutics, among others. 
• Selexipag benefits from established commercial experience in pulmonary arterial hypertension, providing a degree of clinical validation; however, its adoption in arteriosclerosis obliterans/PAD remains constrained by the absence of definitive clinical outcome trials in the PAD setting.
• Regenerative medicine approaches, including CLBS12, are being investigated to address unmet needs by promoting angiogenesis and supporting tissue repair. 
• Similarly, VT-141 represents an emerging approach aimed at restoring perfusion and facilitating recovery of ischemic tissue, although its clinical development remains at an early stage.

Arteriosclerosis Obliterans Competitive Landscape

Some of the arteriosclerosis obliterans drugs under developent include Orforglipron (LY3502970; Eli Lily), Selexipag (NS-304; Nippon Shinyaku), CLBS12 (Lisata Therapeutics), VT-141 (Venturis Therapeutics), REGN7508/Cenvacibart (Regeneron Pharmaceuticals), REGN9933/Amrecibart (Regeneron Pharmaceuticals), BGC101 (BioGenCell), VS-214 (Vasa Therapeutics), and others.

Eli Lilly's Orforglipron is an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist being developed for metabolic conditions, including obesity and type 2 diabetes, with potential cardiovascular benefits that may be relevant to arteriosclerosis obliterans. The therapy supports glycemic control and weight reduction while addressing cardiometabolic risk factors by enhancing insulin secretion, decreasing glucagon release, and slowing gastric emptying. It is also being investigated as a potential treatment for peripheral artery disease (PAD).

Nippon Shinyaku's Selexipag is an oral, selective prostacyclin (IP) receptor agonist being developed by Nippon Shinyaku for the treatment of arteriosclerosis obliterans accompanied by intermittent claudication. Through activation of the IP receptor, selexipag induces vasodilation, reduces platelet aggregation, and inhibits vascular smooth muscle cell proliferation, which may help improve peripheral blood flow. Selexipag is currently undergoing Phase III clinical development in Japan, where its efficacy is being evaluated based on its potential to improve walking ability and exercise capacity in patients with arteriosclerosis obliterans.

The anticipated launch of these emerging therapies are poised to transform the arteriosclerosis obliterans market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the arteriosclerosis obliterans market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the arteriosclerosis obliterans treatment market @ Arteriosclerosis Obliterans Drugs

Arteriosclerosis Obliterans Epidemiology Segmentation

The arteriosclerosis obliterans epidemiology section provides insights into the historical and current arteriosclerosis obliterans patient pool and forecasted trends for the leading markets. The disease shows a strong age-related pattern, with the highest prevalence observed in the 60–74 years age group, reflecting cumulative exposure to cardiovascular risk factors such as smoking, diabetes, and hypertension.

The arteriosclerosis obliterans treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• PAD Diagnosed Prevalent Cases
• Arteriosclerosis Obliterans Prevalent Cases
• Arteriosclerosis Obliterans Diagnosed Prevalent Cases
• Arteriosclerosis Obliterans Cases by Age
• Arteriosclerosis Obliterans Cases by Gender
• Arteriosclerosis Obliterans Treated Cases

Scope of the Arteriosclerosis Obliterans Market Report

• Arteriosclerosis Obliterans Patient Population Forecast
• Arteriosclerosis Obliterans Therapeutics Market Size
• Arteriosclerosis Obliterans Pipeline Analysis
• Arteriosclerosis Obliterans Market Size and Trends
• Arteriosclerosis Obliterans Market Opportunity
• Arteriosclerosis Obliterans Market Unmet Needs
• KOL's Views on Arteriosclerosis Obliterans
• Arteriosclerosis Obliterans Market Access and Reimbursement

Download the report to understand the arteriosclerosis obliterans treatment pipeline @ Arteriosclerosis Obliterans Clinical Trials

Table of Contents

Related Reports

Peripheral Artery Disease Market

Peripheral Artery Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key peripheral artery disease companies, including Ixaka Ltd (formerly Rexgenero), Hemostemix Inc., Lisata Therapeutics, Caladrius Biosciences, Reven Pharmaceuticals, Inc., Helixmith Co., Ltd, and others.

Atherosclerosis Market

Atherosclerosis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key atherosclerosis companies, including Bayer, Janssen, Genentech Inc., BioInvent International AB, GlaxoSmithKline, Merck Sharp & Dohme LLC, Archer Research, Cardionovum GmbH, Sankyo Pharma GmbH, Daiichi Sankyo Inc., AstraZeneca, Omicron Pharmaceuticals, Abbott, Sanofi, Pfizer, and others.

Coronary Artery Disease Market

Coronary Artery Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Coronary Artery Disease companies, including Cytokinetics, Novo Nordisk, BioCardia, Cardurion Pharmaceuticals, Bayer, AstraZeneca, Boehringer Ingelheim, Mesoblast, AskBio, and others.

Peripheral Artery Disease And Stenosis Treatment Devices Market

Peripheral Artery Disease And Stenosis Treatment Devices Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key peripheral artery disease and stenosis treatment devices companies, including Medtronic, Koninklijke Philips N.V., B.Braun SE, Boston Scientific Corporation, BD, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, Rex Medical, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Otivio, Reflow Medical Inc., and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us :
Shruti Thakur  
[email protected]  
+14699457679
www.delveinsight.com 

SOURCE DelveInsight Business Research, LLP

21%

more press release views with 

Request a Demo